Key result
PWI/DCE wash-in rate differentiates treatment responders from non-responders in undifferentiated pleomorphic sarcoma.
Why the study?
Does perfusion-weighted imaging with dynamic contrast enhancement (PWI/DCE) predict pathology-assessed treatment response in patients with undifferentiated pleomorphic sarcoma?
Observational
Does perfusion-weighted imaging with dynamic contrast enhancement (PWI/DCE) predict pathology-assessed treatment response in patients with undifferentiated pleomorphic sarcoma?
PWI/DCE MRI features, specifically TIC-type II curve, low wash-in rate, and capsular enhancement, can accurately predict pathology-assessed treatment response in undifferentiated pleomorphic sarcoma.
May support PWI/DCE for UPS response prediction; leaves open prospective validation before practice change.
), and 60% expressed a TIC-type V (P = 0.06). Semiquantitative wash-in rate (WiR) was able to separate R vs. PR/NR (P = 0.0078). The WiR radiomics displayed significant differences in the first_order_10 percentile (P = 0.0178) comparing R vs. PR/NR at PRT. The PWI/DCE TIC-type II curve, low WiR, and "Capsular" enhancement represent PRT patterns typically observed in successfully treated UPS and demonstrate potential for UPS treatment response assessment.
No takes yet. Share an insight, caveat, or question.
Valenzuela et al. (2024) conducted an observational in Undifferentiated pleomorphic sarcoma (UPS). Perfusion-weighted imaging with dynamic contrast enhancement (PWI/DCE) was evaluated on Treatment response (Responder vs. Partial/Non-Responder) (p=0.0078). Semiquantitative wash-in rate on PWI/DCE significantly differentiated responders from partial/non-responders in undifferentiated pleomorphic sarcoma (P=0.0078).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: